Evidence map›Paper›PMID 32925082›Full record

ReviewJournal of Huntington's disease2020

Large Animal Models of Huntington's Disease: What We Have Learned and Where We Need to Go Next.

David Howland, Zdenka Ellederova, Neil Aronin, Deborah Fernau, Jill Gallagher, Amanda Taylor, Jon Hennebold, Alison R Weiss, Heather Gray-Edwards, Jodi McBride

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of Huntington's disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Reduced DMovement disorders : official journal of the Movement Disorder Society · 2023
    Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Huntington's Disease Gene Hunters: An Expanding Tale.Movement disorders clinical practice · 2022
    Article
  16. Nonhuman Primates in Translational Research.Annual review of animal biosciences · 2022
    Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

David HowlandCHDI Management/CHDI Foundation, Princeton, NJ, USA.
Zdenka EllederovaInstitute of Animal Physiology and Genetics, Libechov, Czech Republic.
Neil AroninHorae Gene Therapy Center and RNA Therapeutics Institute at The University of Massachusetts Medical School, Worcester, MA, USA.
Deborah FernauHorae Gene Therapy Center and RNA Therapeutics Institute at The University of Massachusetts Medical School, Worcester, MA, USA.
Jill GallagherHorae Gene Therapy Center and RNA Therapeutics Institute at The University of Massachusetts Medical School, Worcester, MA, USA.
Amanda TaylorDiplomate, MedVet, American College of Veterinary Internal Medicine - Neurology, Columbus, OH, USA.
Jon HenneboldOregon National Primate Research Center at The Oregon Health and Science University, Portland, OR, USA.
Alison R WeissOregon National Primate Research Center at The Oregon Health and Science University, Portland, OR, USA.
Heather Gray-EdwardsHorae Gene Therapy Center and RNA Therapeutics Institute at The University of Massachusetts Medical School, Worcester, MA, USA.
Jodi McBrideOregon National Primate Research Center at The Oregon Health and Science University, Portland, OR, USA.

Funding

Upgrade of confocal microscopy at the Oregon National Primate Research CenterP51OD011092 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI Bonnie J. Nagel · 2012 to 2026
$203.9M
YR 50 PROJ- ROBERTS PRIMATE ISLETP51RR000163 · NCRR · OREGON REGIONAL PRIMATE RESEARCH CENTER · PI PICKER, LOUIS J. · 1985 to 2011
$140.8M
Cortico-basal ganglia connectivity in a non-human primate model of Huntington's diseaseR01NS099136 · NINDS · OREGON HEALTH & SCIENCE UNIVERSITY · PI MCBRIDE, JODI L. · 2016 to 2020
$3.1M
NCRR NIH HHS P51 RR000163NIH HHS P51 OD011092NINDS NIH HHS R01 NS099136
6 · The paper itself

Abstract

Genetically modified rodent models of Huntington's disease (HD) have been especially valuable to our understanding of HD pathology and the mechanisms by which the mutant HTT gene alters physiology. However, due to inherent differences in genetics, neuroanatomy, neurocircuitry and neurophysiology, animal models do not always faithfully or fully recapitulate human disease features or adequately predict a clinical response to treatment. Therefore, conducting translational studies of candidate HD therapeutics only in a single species (i.e. mouse disease models) may not be sufficient. Large animal models of HD have been shown to be valuable to the HD research community and the expectation is that the need for translational studies that span rodent and large animal models will grow. Here, we review the large animal models of HD that have been created to date, with specific commentary on differences between the models, the strengths and disadvantages of each, and how we can advance useful models to study disease pathophysiology, biomarker development and evaluation of promising therapeutics.

Indexed as

Animals, Genetically ModifiedDisease Models, AnimalHuntington DiseaseAnimalsPrimatesSheepSwineSwine, MiniatureMinipigsnonhuman primatessheeptherapeutics

Identifiers

PMID32925082
PMCPMC7597371

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.